

CURRICULUM VITAE

PART I: General Information

DATE PREPARED: February 23, 2016

Name: A. Oliver Sartor, M.D

Home Address: 1511 Dufossat Street, New Orleans, LA 70115

Work E-Mail: osartor@tulane.edu

Citations: h-index= 52 (per Google Scholar)
12,188 citations

Place of Birth: Shreveport, LA

Education:

1977 B.A. Colorado College, Colorado Springs, CO
1982 M.D. Tulane University School of Medicine, New Orleans, LA

Postdoctoral Training:

1982-1983 Intern in Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Pediatrics Program, Philadelphia, PA
1983-1984 Intern in Medicine, Tulane University School of Medicine
1984-1985 Junior Resident, Internal Medicine, Tulane University School of Medicine
1985-1986 Senior Resident, Internal Medicine, Tulane University School of Medicine
1986-1989 Fellow in Medical Oncology, National Cancer Institute, Bethesda, MD
1989-1990 Senior Staff Fellow, Laboratory of Cellular Development and Oncology, National Institutes of Dental Research, Bethesda, MD

Licensure and Certification:

1985- Louisiana Medical Licensure
1986-lifetime American Board of Internal Medicine Certificate
1989-lifetime American Board of Internal Medicine, Medical Oncology Certificate
1986-1993 Maryland Medical Licensures
1988-1990 Virginia Medical Licensures
2006-2008 Massachusetts Medical Licensure

Academic Appointments:

1990-1993 Senior Investigator, Clinical Pharmacology Branch, National Cancer Institute, Bethesda, MD
1993-1998 Associate Professor of Medicine (with tenure), Section of Hematology/Oncology, Departments of Medicine and Urology, Louisiana State University School of Medicine, Shreveport, LA

1998-2006 Patricia Powers Strong Professor of Oncology (with tenure), Louisiana State University School of Medicine, New Orleans, LA

2002-2006 Adjunct Clinical Professor of Medicine, Tulane University School of Medicine, New Orleans, LA

2006-2007 Associate Professor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2007-2008 Lecturer, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA

2008-2010 Piltz Endowed Professor of Cancer Research in Depts. of Medicine and Urology, Professor of Medicine and Urology (with tenure), Tulane Medical School, New Orleans, LA

2010- C.E. and Bernadine Laborde Professor of Cancer Research and Medical Director, Tulane Cancer Center (with tenure)

Hospital Appointments:

1990-1993 Attending Physician, NIH Clinical Center, Bethesda, MD

1993-1998 Attending Physician, Louisiana State University Hospital, Shreveport, LA

1993-1998 Attending Physician, Willis-Knighton Hospital, Shreveport, LA

1998-2006 Attending Physician, Medical Center of Louisiana at New Orleans, New Orleans, LA

1998-2006 Attending Physician, Memorial Medical Center, New Orleans, LA

2006-2007 Attending Physician, Dana Farber Cancer Institute, Boston, MA

2006-2007 Attending Physician, Brigham and Women's Hospital, Boston, MA

2008- Attending Physician, Tulane University Hospital, New Orleans, LA

Hospital and Health Care Organization Service Responsibilities:

1998-2006 Head, LSU Oncology Services, Medical Center Louisiana, New Orleans

2009- Medical Director, Oncology, Tulane Hospital and Clinics, New Orleans

Major Administrative Responsibilities:

1998-2006 Chief, Hematology/Oncology Section, Department of Medicine, Louisiana State University School of Medicine

1998-2006 Director, Stanley S. Scott Cancer Center, Louisiana State University Health Sciences Center

2002-2006 Co-Director, Louisiana Cancer Research Consortium (comprised of both Louisiana State University Health Sciences Center in New Orleans and Tulane Health Sciences Center, New Orleans, LA)

2006-2007 Director, Clinical Trials Unit, Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute

2010- Medical Director, Tulane Cancer Center

2013- Board Member, Louisiana Cancer Research Consortium

Major Committee Assignments:

1993-1998 Genitourinary Cancer Committee, Member, Southwestern Oncology Group

1995-1998 Institutional Review Board, Member, Louisiana State University School of Medicine

1996-1998 Medical School Admissions Committee, Member, Louisiana State University School of Medicine

1997-1998 Institutional Review Board, Chairman, Louisiana State University School of Medicine

1998-2006 Louisiana Cancer and Lung Trust Fund Board, Member, (Board Appointed by the Governor of Louisiana)

1999-2002 Promotion and Tenure Committee, Member, Department of Medicine, Louisiana State University Health Sciences Center

2000-2002 Promotion and Tenure Committee, Chairman, Department of Medicine, Louisiana State University Health Sciences Center

2001-2005 Clinical Faculty Advisory Committee to the LSU Health Care Network, member, Louisiana State University Health Sciences Center

2003-2009 The Comprehensive Multicenter Prostate Adenocarcinoma Registry (COMPARE), Co-Chairman, sponsored by *sanofi-aventis*.

2003-2005 Louisiana Cancer and Lung Trust Fund Board, Chairman, 2004 (Board Appointed by the Governor of Louisiana)

2003-2006 Executive Committee, Member, Louisiana Cancer Control Partnership

2003-2006 Finance Committee, Member, LSU Health Care Network (organization responsible for overall billing and collections at the LSU Medical School, New Orleans)

2003-2006 Contracts Committee, Member, LSU Health Care Network (responsible for insurance/managed care contracting at the LSU Medical School, New Orleans)

2005-2006 Investment Strategic Planning Committee, *ad hoc* Member, LSU Health Sciences Center Foundation (LSU endowment investments)

2006- Medical Oncology, Co-Chairman, Genitourinary Cancer Committee, Radiation Therapy Oncology Group (RTOG), Now NRG

2006- Medical Oncology Committee, Radiation Therapy Oncology Group (RTOG), Now NRG

2008- Louisiana Cancer and Lung Trust Fund Board, (Board Appointed by the Governor of Louisiana)

2008-2010 Institutional Review Board member, Tulane Medical School

2009- LCRC TURC (Tissue Utilization Research Committee) Committee

2010- Tulane Cancer Center Executive Committee

2010- Chairman, Tulane Cancer Center Strategic Planning Committee

2012- Promotion and Honors Committee, Tulane Medical School (handles both promotion and tenure decisions School Wide)

2013 FDA Public Workshop Panelist: Clinical Trial Design Issues - Drug & Device Development for Localized Prostate Cancer

2013- MEDCAC (Medicare Evidence Development & Coverage Advisory Committee) Panel Member (health and Human Services)

2013- Chairman, Commission on Cancer Committee at Tulane

2013- LCRC (Louisiana Cancer Research Consortium) Board of Directors

2014- Ad hoc advisor to the FDA on prostate cancer matters

2014- Ad hoc Consultant to Botswana Government on National Cancer Plan

Teaching leadership:

- 1990-1993 Medical Oncology Attending, National Cancer Institute, Bethesda, MD, inpatient oncology service ~2 months/year (fellows)
- 1990-1993 Medical Oncology Attending, National Cancer Institute, Bethesda, MD, outpatient oncology clinics, 12 months/year (fellows)
- 1993-1998 Medical Oncology Attending, LSU Medical School and VA Medical Center, Shreveport, LA, inpatient oncology service ~2 months/year (fellows, residents, students)
- 1993-1998 Medical Oncology Attending, outpatient oncology attending, LSU Medical School and VA Medical Center, Shreveport, LA, outpatient oncology service, 12 months/year (fellows, residents a portion of the time)
- 1998-2005 Medical Oncology Attending, LSU Medical School, New Orleans, LA, inpatient oncology service ~2 months/year (fellows, residents, students)
- 1998-2005 Medical Oncology Attending, outpatient oncology attending, LSU Medical School, New Orleans, LA, outpatient oncology service, 12 months/year (fellows, residents a portion of the time)
- 2006-2007 Medical Oncology Attending, Solid Tumor Service, Brigham & Women's Hospital, Boston, MA, 4-6 weeks/year (residents)
- 2006-2007 Medical Oncology Attending, outpatient GU oncology clinics, Dana-Farber Cancer Institute, Boston, MA, 12 months/year (fellows, a portion of the time)
- 2008- Tulane Cancer Center Attending, Inpatient and outpatient services

Scientific Advisory Boards:

- 1999- Center for Prostate Disease Research-Walter Reed Hospital & US Department of Defense, Washington, DC
- 2000-2004 Atrix Laboratories, Ft. Collins, CO
- 2000-2006 Metastatin Pharmaceuticals, Washington, DC
- 2004-2006 Patient Advocates Against Advanced Cancer (PAACT), Grand Rapids, MI
- 2004-2011 Theralogix, Rockville, MD
- 2006-2011 Prostate Cancer Prevention Trial P01
- 2010- Bellicum
- 2012- Mt. Sinai Tisch Cancer Center External Scientific Advisory Board
- 2013- Biscayne Pharmaceuticals
- 2014- AJCC staging committee (8th edition) for male genital expert panel

Miscellaneous ad hoc Advisory Boards and Consultant Agreements:

- 1993 Henri-Beaufour Institute (France)
- 1993-1995 Immunex (USA)
- 1995 DuPont (USA)
- 1996 Schering (USA)
- 1996-2008 Cytogen (USA)
- 1996 Debiopharm (Swiss)
- 1996 Janssen (USA)
- 1996-1998 Berlex (German)
- 2003-2009 GPC Biotech (German)

2003-2004	Atrix Laboratories (USA)
2003-2005	Bracco (Italy)
2004-2007	Negma-Lerads (France)
2004-2005	Abbott (USA)
2004-	<i>sanofi</i> (France)
2004-	Dendreon
2005	Novacea (USA)
2005	Astellia (Japan)
2005	Novartis (Swiss)
2005-2006	Spectrum Pharmaceuticals (USA)
2006-2007	QLT, Inc. (Canada)
2006	Roche (Swiss)
2006-2007	Sermo (USA)
2006	TEVA (Israel)
2006-2010	GlaxoSmithKline (UK)
2006	General Electric (USA)
2007	Cleveland Biolabs (USA)
2007-	Pfizer (USA)
2007-2008	Ausio Pharmaceuticals, LLC (USA)
2007-	OncoGenex (Canada)
2007	Bind Biosciences (USA)
2007-	Algeta (Norway)
2008	EUSA (USA)
2008-	Tolmar (Argentina)
2009	Ascenta (USA)
2009-2012	Takeda (Japan)
2009-2011	Celgene
2009-2011	BMS
2009-	Medivation
2009-2011	Amgen
2009-	Bellicum
2010	ExonHit
2010-	Exelixis
2011-	Bayer
2010-2011	Centocor (JNJ)
2011-	List truncated as it became too numerous to detail

Independent Data Safety and Monitoring Committees:

2004-2009	Chairman, IDMC, Dendreon, Provenge Vaccine Trial 9902B phase III IMPACT study
2007-2009	Chairman, Dendreon, Provenge Vaccine Trial PO-7 Study
2006-2012	IDMC (sole member), OncoGenex, OGX-427-01 Trial
2008-2010	Chairman, IDMC, Pfizer, A6181120 (Phase III study in hormone-refractory prostate cancer with sunitinib/prednisone versus prednisone
2008-2013	IDMC, Pfizer, A4061032 (Phase III Trial of axitinib in metastatic renal cancer). Chairman, 2010-

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.